
Medical Device Design Changes: Bridging Chemical and Biological Equivalence in a Changing Regulatory Landscape
- When
- Length
- 1 hr 30 min
- Platform
- Zoom
- Topic
- Medical & Clinical
- Price
- Free
About this webinar
Hosted by the SOT Medical Device and Combination Product Specialty Section
Medical device design and material changes are increasingly common due to evolving supply chain constraints, manufacturing innovations, and lifecycle product improvements. These changes present ongoing challenges in demonstrating continued biological safety, particularly when determining whether chemical equivalence alone is sufficient to support a biological risk assessment or whether additional biological testing is required.
This webinar will explore current regulatory expectations across major frameworks, including FDA and EU MDR, and provide practical strategies for evaluating design changes using a risk-based, science-driven approach. Speakers will address the use of material, process, and analytical data to support biological safety decisions, including the role and limitations of comparative extractables and leachables studies.
Through expert perspectives and real-world case studies, the session will highlight challenges in defining equivalence, navigating regulatory pathways, managing uncertainty, and balancing efficiency with patient safety. A multidisciplinary discussion will provide toxicologists, regulatory professionals, and medical device developers with practical considerations for evaluating material and manufacturing process changes.
Speakers
James Kleinedler, PhD, Director, Regulatory Safety, Medtronic
Adam Kozak, Senior Director, Quality, Edwards Lifesciences
Kevin Trankler, PhD, Senior Director, Medical Testing, Eurofins, Medical Device Services
Sherry Parker, PhD, President, SParker Toxicology Consulting LLC
William Wustenberg, DVM, President and Principal Consultant, Mycroft Medical LLC



